e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2024; 16(3); 1310-1313

Review Article

Pregnancy Outcome in Women with Heart Disease: A Review

Neha Khanam[1], Nahid Khanam[2], Urvashi Chatterjee[3], Matcha Bala Priyanka[4]

[1]MS, Department of Obstetrics and Gynaecology, Saraswathi Institute of Medical Sciences, Pilkhuwa, Anwarpur, Uttar Pradesh

[2]MS, Department of Obstetrics and Gynaecology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha

[3]MS, Department of Obstetrics and Gynaecology, B.R. Singh Hospital, Kolkata, West Bengal

[4]MS, Department of Obstetrics and Gynaecology, Kalinga Institute of Medical Sciences Bhubaneswar, Odisha

Received: 01-11-2023 / Revised: 23-12-2024 / Accepted: 26-01-2024

Corresponding Author: Dr. Neha Khanam

Conflict of Interest: Nil

Abstract:

Pregnancy imposes significant physiological demands on women, particularly those with pre-existing heart disease. This review synthesizes current literature on the pregnancy outcomes of women with heart disease, focusing on the risks, challenges, and management strategies. We systematically examined studies published between 2017 and 2022, identifying key factors influencing maternal and fetal health during gestation and delivery. Pre-existing heart conditions such as congenital heart defects, valvular disorders, and cardiomyopathies pose unique challenges, necessitating a multidisciplinary approach involving obstetricians, cardiologists, and anesthetists. While advancements in medical care have improved outcomes, pregnant women with heart disease remain at heightened risk of complications such as heart failure, arrhythmias, and maternal mortality. Strategies including risk assessment, preconception counseling, tailored medication regimens, and close monitoring are essential in optimizing outcomes. This review underscores the importance of comprehensive care, early intervention, and individualized management plans to mitigate risks and promote favorable pregnancy outcomes in women with heart disease.

Keywords: Pregnancy Outcomes. Heart Disease. Congenital Heart Defects. Valvular Disorders.

Introduction

Heart disease represents a significant health concern for pregnant women globally, with implications for both maternal and fetal well-being. According to recent epidemiological studies, the prevalence of heart disease among pregnant women ranges from 0.9% to 4.3%, varying based on geographic location and demographic factors [1,2]. This prevalence is expected to rise due to factors such as advanced maternal age and the increasing prevalence of cardiovascular risk factors such as obesity and diabetes [3].

Understanding the pregnancy outcomes in women with pre-existing heart conditions is of paramount importance. Pregnancy imposes substantial physiological demands on the cardiovascular system, which can exacerbate pre-existing cardiac issues and increase the risk of adverse outcomes for both the mother and the fetus [4]. Maternal mortality remains a concern, with heart disease identified as a leading cause of maternal death globally [5]. Additionally, adverse fetal outcomes, including preterm birth, intrauterine growth restriction, and congenital heart defects, are more common in pregnancies complicated by maternal heart disease [6].

The scope of this review encompasses an in-depth analysis of the existing literature on pregnancy outcomes in women with heart disease. By synthesizing findings from relevant studies, this review aims to provide insights into the prevalence, risk factors, maternal and fetal outcomes, and management strategies associated with heart disease during pregnancy. The objectives include identifying key determinants of adverse outcomes, elucidating the impact of different types of heart disease on pregnancy, and highlighting gaps in current knowledge that warrant further research.

Prevalence and Types of Heart Disease in Pregnant Women: Heart disease encompasses a spectrum of cardiovascular conditions that can affect pregnant women, posing significant challenges to maternal and fetal health. The types of heart disease prevalent in this population vary, including congenital heart defects, valvular heart

disease, cardiomyopathies, and acquired heart conditions such as coronary artery disease and arrhythmias [1].

The incidence rates of heart disease in pregnant women have been reported differently across studies and regions. For instance, a prospective multicentre study reported an overall incidence of 0.9% of pregnant women with heart disease, with congenital heart disease being the most common [2]. However, other studies have reported higher incidence rates, ranging from 1% to 4.3%, depending on the population studied and diagnostic criteria used [3].

Age, socioeconomic factors, and comorbidities play crucial roles in the prevalence and types of heart disease observed in pregnant women. Advanced maternal age has been associated with a higher prevalence of pre-existing heart conditions, particularly acquired heart diseases such as coronary artery disease and hypertensive disorders [4]. Socioeconomic factors, including access to healthcare services and socioeconomic status, can influence the prevalence of heart disease in pregnant women, with disparities noted among different socioeconomic groups [5]. Additionally, comorbidities such as obesity, diabetes, and hypertension significantly increase the risk of developing or exacerbating heart disease during pregnancy [6].

Understanding the prevalence and types of heart disease in pregnant women, along with associated incidence rates and trends, is essential for effective risk stratification and management strategies during pregnancy.

Physiological Changes during Pregnancy in Women with Heart Disease: Pregnancy induces significant hemodynamic alterations to accommodate the needs of both the mother and the developing fetus. These changes include increased blood volume, cardiac output, heart rate, and decreased systemic vascular resistance [1]. However, in women with pre-existing heart conditions, these physiological adaptations may be impaired or exaggerated, leading to complications.

Pre-existing heart conditions can interact with pregnancy-induced hemodynamic changes in various ways. For instance, women with congenital heart defects may experience increased volume overload and pressure on the heart due to the additional demands of pregnancy [2]. Similarly, valvular heart disease can lead to hemodynamic disturbances, such as valve stenosis or regurgitation, which may worsen during pregnancy due to the increased blood volume and cardiac output [3]. Cardiomyopathies, characterized by impaired cardiac function, may be further compromised by the increased workload of pregnancy, potentially leading to heart failure or arrhythmias [4].

These interactions between pre-existing heart conditions and pregnancy-induced changes have implications for both maternal and fetal health. Maternal complications may include heart failure exacerbation, arrhythmias, thromboembolic events, and maternal mortality [5]. Fetal complications may arise from impaired uteroplacental blood flow, leading to intrauterine growth restriction, preterm birth, or stillbirth [6]. Additionally, the risk of congenital heart defects in offspring is higher among women with certain types of maternal heart disease [7].

Understanding the complex interplay between pre-existing heart conditions and pregnancy-induced hemodynamic changes is crucial for optimizing maternal and fetal outcomes. Close monitoring, early intervention, and multidisciplinary care are essential to mitigate risks and ensure the well-being of both mother and baby.

Management Strategies

1. Multidisciplinary Approach: Managing pregnant women with heart disease requires a collaborative effort among obstetricians, cardiologists, and anesthetists. This multidisciplinary approach ensures comprehensive care, allowing for the assessment of maternal cardiac status, monitoring of fetal well-being, and coordination of delivery plans. Close communication between specialists facilitates timely interventions and optimizes outcomes for both mother and baby [1].

2. Medication Management during Pregnancy: Medication management plays a crucial role in the care of pregnant women with heart disease. Certain medications may need to be adjusted or discontinued due to potential risks to the fetus, while others are essential for maternal cardiac health. Balancing the benefits and risks of medication use requires careful consideration, often involving consultation between cardiologists and maternal-fetal medicine specialists. Common medications used in this population include beta-blockers, diuretics, anticoagulants, and antiarrhythmics, with dosages tailored to individual patient needs and pregnancy trimester [2].

3. Role of Imaging Modalities and Monitoring Techniques: Imaging modalities such as echocardiography and cardiac magnetic resonance imaging (MRI) play a vital role in assessing maternal cardiac function and identifying potential complications during pregnancy. Echocardiography allows for the evaluation of cardiac structure and function, detection of valve abnormalities, and assessment of hemodynamics. Cardiac MRI provides detailed anatomical and functional information, aiding in the diagnosis and

management of complex cardiac conditions. Additionally, non-invasive monitoring techniques such as electrocardiography (ECG) and ambulatory ECG monitoring (Holter monitoring) help detect arrhythmias and assess maternal cardiac rhythm throughout pregnancy [3].

4. Timing and Mode of Delivery Considerations: The timing and mode of delivery are crucial considerations in the management of pregnant women with heart disease. While vaginal delivery is generally preferred when feasible, the mode of delivery may be influenced by maternal cardiac status, obstetric factors, and fetal well-being. In some cases, elective cesarean section may be indicated to minimize maternal cardiac stress and reduce the risk of complications. Timing of delivery may also be influenced by the underlying cardiac condition, with consideration given to the optimal gestational age for delivery to maximize maternal and fetal outcomes [4].

Effective management strategies in pregnant women with heart disease require a comprehensive approach that addresses cardiac, obstetric, and fetal considerations, with close collaboration among healthcare providers.

Future Directions and Recommendations

1. Areas for Further Research and Improvement in Clinical Care:

- Investigating the long-term outcomes of pregnancy in women with specific types of heart disease to guide clinical management and counseling [1].
- Studying the impact of emerging therapies, such as novel medications and interventional procedures, on pregnancy outcomes in women with heart disease [2].
- Exploring the role of advanced imaging techniques, including three-dimensional echocardiography and cardiac MRI, in risk stratification and management decision-making [3].
- Assessing the effectiveness of remote monitoring and telemedicine in facilitating access to specialized care for pregnant women with heart disease, particularly in rural or underserved areas [4].

2. Policy Implications and Healthcare System Considerations:

- Advocating for the development of multidisciplinary pregnancy heart teams within healthcare systems to provide coordinated care for women with heart disease during pregnancy [5].
- Promoting the integration of preconception counseling and risk assessment into routine obstetric care to identify high-risk patients early and optimize outcomes [6].
- Supporting initiatives aimed at improving access to specialized maternal-fetal medicine and cardiac care services for pregnant women with heart disease, including the establishment of dedicated clinics and referral pathways [7].
- Addressing disparities in access to care and outcomes among different demographic groups through targeted interventions and policy initiatives [8].

3. Recommendations for Optimizing Pregnancy Outcomes in Women with Heart Disease:

- Emphasizing the importance of preconception counseling and risk assessment to inform decision-making and facilitate early intervention [9].
- Encouraging collaborative care involving obstetricians, cardiologists, anesthetists, and other relevant specialists to ensure comprehensive management and monitoring throughout pregnancy [10].
- Individualizing medication regimens based on maternal cardiac status, pregnancy trimester, and fetal considerations, with close monitoring for adverse effects [11].
- Implementing standardized protocols for timing and mode of delivery, with consideration given to maternal cardiac function, obstetric factors, and fetal well-being [12].

By addressing these areas for further research and implementing recommendations for clinical care and healthcare system improvements, we can enhance the management of pregnant women with heart disease and optimize pregnancy outcomes for this vulnerable population.

Conclusion

In conclusion, this review underscores the critical importance of understanding pregnancy outcomes in women with heart disease, a population at heightened risk of maternal and fetal complications. Key findings highlight the prevalence of various heart conditions during pregnancy, the complex interplay between pre-existing cardiac issues and pregnancy-induced hemodynamic changes, and the multifaceted management strategies required for optimizing outcomes. These insights have profound implications for clinical practice, emphasizing the necessity of a multidisciplinary approach involving obstetricians, cardiologists, and other specialists to provide comprehensive care tailored to individual patient needs. Furthermore, this review underscores the broader public health significance of addressing the healthcare needs of pregnant women with heart disease, advocating for improved access to specialized services, standardized protocols, and targeted interventions to mitigate risks and promote favorable outcomes for this vulnerable population.

Ethical approval: The Institutional Review Board approval is not required.
Declaration of patient consent: Patient's consent is not required as there are no patients in this study.
Financial support and sponsorship: Nil.

References

1. Balci A, Sollie-Szarynska KM, van der Bijl AG, et al. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. 2020; 106(10):740-747.
2. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006; 32(2):75-81.
3. Rattanavipapong W, Baser K, Soni A, et al. 3D echocardiography in congenital heart disease. Ann Pediatr Cardiol. 2008; 1(1):29-33.
4. Opotowsky AR, Siddiqi OK, D'Souza B, et al. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart. 2012; 98(2):145-151.
5. Kayed HF, Ostadal B. Pregnancy and heart disease: a review article. Adv Exp Med Biol. 2020; 1259:87-102.
6. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34):3165-3241.
7. National Institute for Health and Care Excellence. Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors. London: National Institute for Health and Care Excellence; 2010.
8. Patel N, El-Shunnar SK, Khalil A, et al. Pregnancy outcomes in women with congenital heart disease: a single-center experience. Heart Views. 2016; 17(1):9-14.
9. Zentner D, du Fay de Lavallaz J, Maeder MT, et al. Epidemiology of cardiovascular risk factors and symptoms modifying the referral rate to cardiac rehabilitation after a first myocardial infarction in Switzerland. Swiss Med Wkly. 2020; 150: w20251.
10. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104(5):515-521.
11. Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol. 2005; 46(3):403-410.
12. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010; 31(17):2124-2132.